First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

BACKGROUND: Budigalimab is a humanized, recombinant immunoglobulin G1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783908/
https://www.ncbi.nlm.nih.gov/pubmed/34216247
http://dx.doi.org/10.1007/s00262-021-02973-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783908/
https://www.ncbi.nlm.nih.gov/pubmed/34216247
http://dx.doi.org/10.1007/s00262-021-02973-w

Ejemplares similares